NEW YORK (GenomeWeb News) – Bioheart, a Sunrise, Fla.-based developer of stem cell therapies for cardiovascular diseases, today said that it has entered into a global distribution and OEM pact for Life Technologies to sell the firm’s myoblast cell-based research products to life science researchers.
 
Bioheart said that the myoblast products will complement Life Technologies’ current portfolio of reagents for isolating, characterizing, expanding, and differentiating stem cells.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.